CytoSorbents Corporation (CTSO)

[biotech48]

• Data from the business valuation community, Mergerstat® in particular, has generally indicated a control premium percentage in takeover situations from the low 20’s to high 30’s over the past decade. Much of the premium in these situations is driven either by a formal process or by the threat of a process leading to a preemptive bid from the acquirer.

• For the 100+ public companies acquired in 2013 with pre-announcement market caps over $50 million, the average premium to the share price a month before the announcement was 37%. [1]. Looking back over the past 10 years, the premium has also averaged 37%.

• For targets under $100 million market cap, premiums have tended to be higher. Over the past 10 years, transactions in this range averaged a 50% one-month premium. Targets this size commanding the highest premiums tend to be biotech and software/IT businesses.

http://merger.com/ma-question-dont/